Tandutinib (MLN518, CT53518, NSC-726292)

Description: Tandutinib (formerly also known as MLN-518, CT-53518, D06005, NSC726292), a piperazinyl quinazoline, is a novel, potent and selective FLT3 inhibitor/antagonist with potential antitumor activity. It inhibits FLT3 with an IC50 of 0.22 uM. Tandutinib also inhibits PDGFR and c-Kit, and shows 15 to 20-fold higher potency for inhibiting FLT3 over CSF-1R, and > 100-fold higher selectivity over FGFR, EGFR and KDR. Tandutinib has potential antineoplastic activity by inhibiting the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis.

References: Cancer Cell. 2002 Jun; 1(5):421-32; Blood. 2004 Nov 1; 104(9):2912-8.

Chemical Name: N-(4-isopropoxyphenyl)-4-(6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-yl)piperazine-1-carboxamide

InChi Key: UXXQOJXBIDBUAC-UHFFFAOYSA-N

InChi Code: InChI=1S/C31H42N6O4/c1-23(2)41-25-10-8-24(9-11-25)34-31(38)37-17-15-36(16-18-37)30-26-20-28(39-3)29(21-27(26)32-22-33-30)40-19-7-14-35-12-5-4-6-13-35/h8-11, 20-23H, 4-7, 12-19H2, 1-3H3, (H, 34, 38)

SMILES Code: O=C(N1CCN(C2=C3C=C(OC)C(OCCCN4CCCCC4)=CC3=NC=N2)CC1)NC5=CC=C(OC(C)C)C=C5